Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Guardion Health Sciences, Inc. stock logo
GHSI
Guardion Health Sciences
$3.22
-2.1%
$3.24
$3.04
$18.00
$4.35M0.73105,261 shs4,700 shs
Provectus Biopharmaceuticals, Inc. stock logo
PVCT
Provectus Biopharmaceuticals
$0.08
+1.2%
$0.08
$0.04
$0.15
$31.77M0.75160,841 shs9,200 shs
Regulus Therapeutics Inc. stock logo
RGLS
Regulus Therapeutics
$8.16
$8.03
$0.83
$8.35
$564.92M0.35995,388 shsN/A
China SXT Pharmaceuticals, Inc. stock logo
SXTC
China SXT Pharmaceuticals
$1.71
-3.4%
$1.74
$0.95
$11.92
$205.37M1.181.19 million shs38,029 shs
Options Trading Made Easy - Download Now Cover

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Guardion Health Sciences, Inc. stock logo
GHSI
Guardion Health Sciences
0.00%0.00%0.00%0.00%-67.14%
Provectus Biopharmaceuticals, Inc. stock logo
PVCT
Provectus Biopharmaceuticals
-1.43%+2.16%-1.82%-21.33%-49.09%
Regulus Therapeutics Inc. stock logo
RGLS
Regulus Therapeutics
0.00%0.00%-1.69%+374.42%+385.71%
China SXT Pharmaceuticals, Inc. stock logo
SXTC
China SXT Pharmaceuticals
0.00%-0.56%-8.76%-33.08%-79.13%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Guardion Health Sciences, Inc. stock logo
GHSI
Guardion Health Sciences
N/AN/AN/AN/AN/AN/AN/AN/A
Provectus Biopharmaceuticals, Inc. stock logo
PVCT
Provectus Biopharmaceuticals
N/AN/AN/AN/AN/AN/AN/AN/A
Regulus Therapeutics Inc. stock logo
RGLS
Regulus Therapeutics
1.6373 of 5 stars
2.15.00.00.00.03.30.0
China SXT Pharmaceuticals, Inc. stock logo
SXTC
China SXT Pharmaceuticals
0.1576 of 5 stars
0.03.00.00.00.00.00.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Guardion Health Sciences, Inc. stock logo
GHSI
Guardion Health Sciences
0.00
N/AN/AN/A
Provectus Biopharmaceuticals, Inc. stock logo
PVCT
Provectus Biopharmaceuticals
0.00
N/AN/AN/A
Regulus Therapeutics Inc. stock logo
RGLS
Regulus Therapeutics
2.29
Hold$8.504.17% Upside
China SXT Pharmaceuticals, Inc. stock logo
SXTC
China SXT Pharmaceuticals
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest SXTC, RGLS, GHSI, and PVCT Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/1/2025
Regulus Therapeutics Inc. stock logo
RGLS
Regulus Therapeutics
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Equal Weight$9.00
4/30/2025
Regulus Therapeutics Inc. stock logo
RGLS
Regulus Therapeutics
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeStrong-Buy ➝ Hold
4/30/2025
Regulus Therapeutics Inc. stock logo
RGLS
Regulus Therapeutics
Leerink Partnrs
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeStrong-Buy ➝ Hold
4/30/2025
Regulus Therapeutics Inc. stock logo
RGLS
Regulus Therapeutics
Leerink Partners
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Market Perform$7.00
4/30/2025
Regulus Therapeutics Inc. stock logo
RGLS
Regulus Therapeutics
Canaccord Genuity Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Hold$28.00 ➝ $11.00
4/30/2025
Regulus Therapeutics Inc. stock logo
RGLS
Regulus Therapeutics
Jones Trading
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Hold$8.00 ➝ $7.00
(Data available from 7/10/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Guardion Health Sciences, Inc. stock logo
GHSI
Guardion Health Sciences
$12.25M0.35$0.14 per share23.15$6.39 per share0.50
Provectus Biopharmaceuticals, Inc. stock logo
PVCT
Provectus Biopharmaceuticals
$620K51.86N/AN/A($0.01) per share-7.65
Regulus Therapeutics Inc. stock logo
RGLS
Regulus Therapeutics
N/AN/AN/AN/A$1.17 per shareN/A
China SXT Pharmaceuticals, Inc. stock logo
SXTC
China SXT Pharmaceuticals
$1.93M102.80N/AN/A$243.66 per share0.01
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Guardion Health Sciences, Inc. stock logo
GHSI
Guardion Health Sciences
$160K$4.870.66N/A22.79%-73.69%-48.17%N/A
Provectus Biopharmaceuticals, Inc. stock logo
PVCT
Provectus Biopharmaceuticals
-$4.76MN/A0.00N/A-815.81%N/A-644.80%8/11/2025 (Estimated)
Regulus Therapeutics Inc. stock logo
RGLS
Regulus Therapeutics
-$46.36M-$0.73N/AN/AN/AN/A-57.53%-53.26%8/6/2025 (Estimated)
China SXT Pharmaceuticals, Inc. stock logo
SXTC
China SXT Pharmaceuticals
-$3.10MN/A0.00N/AN/AN/AN/AN/A

Latest SXTC, RGLS, GHSI, and PVCT Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/8/2025Q1 2025
Regulus Therapeutics Inc. stock logo
RGLS
Regulus Therapeutics
-$0.29-$0.15+$0.14-$0.15N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Guardion Health Sciences, Inc. stock logo
GHSI
Guardion Health Sciences
$5.00155.28%N/A102.67%N/A
Provectus Biopharmaceuticals, Inc. stock logo
PVCT
Provectus Biopharmaceuticals
N/AN/AN/AN/AN/A
Regulus Therapeutics Inc. stock logo
RGLS
Regulus Therapeutics
N/AN/AN/AN/AN/A
China SXT Pharmaceuticals, Inc. stock logo
SXTC
China SXT Pharmaceuticals
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Guardion Health Sciences, Inc. stock logo
GHSI
Guardion Health Sciences
N/A
16.68
16.59
Provectus Biopharmaceuticals, Inc. stock logo
PVCT
Provectus Biopharmaceuticals
N/A
0.11
0.11
Regulus Therapeutics Inc. stock logo
RGLS
Regulus Therapeutics
N/A
16.31
16.31
China SXT Pharmaceuticals, Inc. stock logo
SXTC
China SXT Pharmaceuticals
N/AN/AN/A
CompanyEmployeesShares OutstandingFree FloatOptionable
Guardion Health Sciences, Inc. stock logo
GHSI
Guardion Health Sciences
101.35 million1.33 millionNot Optionable
Provectus Biopharmaceuticals, Inc. stock logo
PVCT
Provectus Biopharmaceuticals
4420.28 million358.50 millionNot Optionable
Regulus Therapeutics Inc. stock logo
RGLS
Regulus Therapeutics
3069.23 million66.22 millionOptionable
China SXT Pharmaceuticals, Inc. stock logo
SXTC
China SXT Pharmaceuticals
90116.03 million111.45 millionNot Optionable

Recent News About These Companies

China SXT Pharmaceuticals, Inc. (SXTC) - Yahoo Finance
China SXT Pharmaceuticals Inc Ordinary Shares
China SXT Pharmaceuticals regains compliance with Nasdaq
China SXT Pharmaceuticals Inc trading resumes
China SXT Pharmaceuticals Inc trading halted, volatility trading pause
China SXT Pharmaceuticals Inc trading halted, news pending
china sxt pharmaceuticals - SXTC

New MarketBeat Followers Over Time

Media Sentiment Over Time

Guardion Health Sciences stock logo

Guardion Health Sciences NASDAQ:GHSI

Guardion Health Sciences, Inc., a clinical nutrition company, develops and distributes clinically supported dietary supplements and medical foods in North America, Europe, and internationally. The company offers GlaucoCetin, a dietary supplement to support mitochondrial function with additional antioxidants to help reduce oxidative stress and increase blood flow throughout the body for enhanced eye support and ocular health; and Lumega-Z, a medical food that replenishes and restores the macular protective pigment. It also provides Viactiv Omega Boost Gel Bites, an omega-3 fish oil dietary supplement. The company distributes medical foods products through e-commerce website, guardionhealth.com. Guardion Health Sciences, Inc. was founded in 2009 and is headquartered in Houston, California.

Provectus Biopharmaceuticals stock logo

Provectus Biopharmaceuticals OTCMKTS:PVCT

$0.08 +0.00 (+1.19%)
As of 09:43 AM Eastern

Provectus Biopharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing immunotherapy medicines based on halogenated xanthenes in the United States. The company's lead molecule is rose bengal sodium (RBS). Its clinical development programs include PV-10 for the treatment of stage III and IV melanoma and different types of liver cancers; PH-10 for the treatment of psoriasis and atopic dermatitis, and skin inflammation; and PV-305 for the treatment of infectious keratitis. It is also developing oral formulations for adult solid tumor cancers, as well as refractory and relapsed pediatric, and other blood cancers comprising leukemias; PV-10 for the treatment of relapsed and refractory pediatric solid tumor cancers; and other formulations for the treatment of cutaneous canine cancers and healing of full-thickness cutaneous wounds. In addition, the company develops oral and intranasal formulations for the treatment of severe acute respiratory syndrome coronavirus 2; gram-positive and gram-negative bacterial infections; oral bacterial infections; and fungal infections, as well as vertebrate development, wound healing, and tissue regrowth. It has collaboration agreement with Bascom Palmer Eye Institute; and University of Miami. The company was formerly known as Provectus Pharmaceuticals, Inc. and changed its name to Provectus Biopharmaceuticals, Inc. in December 2013. Provectus Biopharmaceuticals, Inc. was founded in 2002 and is based in Knoxville, Tennessee.

Regulus Therapeutics stock logo

Regulus Therapeutics NASDAQ:RGLS

$8.16 0.00 (0.00%)
As of 06/25/2025

Regulus Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RGLS8429, an anti-miR next generation oligonucleotide targeting miR-17, which is in Phase 1b clinical trial for the treatment of autosomal dominant polycystic kidney disease. The company is also developing a pipeline of preclinical drug products for target organ-selective delivery strategies. Regulus Therapeutics Inc. was incorporated in 2007 and is headquartered in San Diego, California.

China SXT Pharmaceuticals stock logo

China SXT Pharmaceuticals NASDAQ:SXTC

$1.71 -0.06 (-3.39%)
Closing price 04:00 PM Eastern
Extended Trading
$1.71 0.00 (-0.06%)
As of 07:50 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

China SXT Pharmaceuticals, Inc., a pharmaceutical company, engages in the research, development, manufacture, marketing, and sale of traditional Chinese medicine pieces (TCMP) in China. The company offers advanced, fine, and regular TCMP products, and raw medicinal material, such as ChenXiang, SanQiFen, HongQi, SuMu, JiangXiang, CuYanHuSuo, XiaTianWu, LuXueJing, XueJie, ChaoSuanZaoRen, HongQuMi, ChuanBeiMu, HuangShuKuiHua, WuWeiZi, DingXiang, RenShen, QingGuo, JueMingZi, and ShaRen. It provides its products under the Suxuantang, Hui Chun Tang, and Tong Ren Tang brands. The company had an end-customer base of pharmaceutical companies, chain pharmacies, and hospitals in 10 provinces and municipalities in China. China SXT Pharmaceuticals, Inc. was founded in 2005 and is headquartered in Taizhou, China.